SWP
AGIO icon

Stratos Wealth Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Stratos Wealth Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$15K – 897
2018
Q3 		$15K Buy
+200
New +$16.1K ﹤0.01% 1993
2018
Q2 		– Sell
-200
Closed -$16K – 1003
2018
Q1 		$16K Hold
200
– – ﹤0.01% 2094
2017
Q4 		$11K Buy
+200
New +$12.6K ﹤0.01% 2114

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Stratos Wealth Partners's AGIO Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 200 shares — an estimated $15K sold.

Stratos Wealth Partners first reported a position in AGIO in Q4 2017 and held it in 3 quarters. The position peaked at $16K in Q1 2018. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 200 Agios Pharmaceuticals shares in Q4 2018, an estimated $15K.
  • Stratos Wealth Partners first reported a position in Agios Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Agios Pharmaceuticals position peaked at $16K in Q1 2018.
  • 196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.